CN1134151A - Pyrazine carboxamide derivs., their production and their use in medicaments - Google Patents

Pyrazine carboxamide derivs., their production and their use in medicaments Download PDF

Info

Publication number
CN1134151A
CN1134151A CN94194016A CN94194016A CN1134151A CN 1134151 A CN1134151 A CN 1134151A CN 94194016 A CN94194016 A CN 94194016A CN 94194016 A CN94194016 A CN 94194016A CN 1134151 A CN1134151 A CN 1134151A
Authority
CN
China
Prior art keywords
formula
group
compound
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94194016A
Other languages
Chinese (zh)
Inventor
奥托·鲁斯
乔格·斯佩克
沃尔特·洛赛尔
迪特里希·阿恩特斯
沃尔-迪特里希·贝龙特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim GmbH
Publication of CN1134151A publication Critical patent/CN1134151A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

New compounds of general formula (I) are provided which are explained in the specification can be prepared by a variety of methods. The compounds may be used in pharmaceutical compositions.

Description

New pyrazinecarboxamide derivatives, its preparation method and the application in pharmaceutical composition thereof
The present invention relates to pyrazinecarboxamide derivatives, its preparation method and the application aspect its pharmaceutical compositions.
One aspect of the present invention provides formula (I) compound and acid salt thereof Wherein A represents to be connected in by nitrogen-atoms the following radicals of Zinamide system :-C mH 2m-NR 4--C mH 2m-NR 4-C pH 2p-NR 4The NR of '-- 4-C mH 2m-NR 4'
Figure A9419401600102
R 1Expression hydrogen, fluorine, chlorine, C 1-4-alkyl, C 3-7Cycloalkyl, C 1-4-alkoxyl group, trifluoromethyl, phenyl, benzyl, phenyl-low alkyl group, phenyl-low-grade alkenyl, phenyl-low-grade alkynyl or phenoxy group, wherein phenyl can contain at the most 3 and is selected from C 1-4-alkyl, C 1-4-alkoxyl group, CF 3, F, Cl or CN substituting group; R 2Expression following formula group
Figure A9419401600112
Figure A9419401600131
Figure A9419401600141
R wherein 3, R 4And R 4' can be identical or different, expression hydrogen or C 1-4-alkyl, or R 4Or R 4' also can represent phenyl, benzyl or C 3-7-cycloalkyl; R 5And R 6Can be identical or different, expression hydrogen, methyl, methoxyl group, hydroxyl or halogen; R 7Expression hydrogen, C 1-4-alkyl, benzyl or benzyloxy; R 8And R 9Identical or different, expression hydrogen, C 1-4-alkyl, phenyl or halogen; R 10Expression hydrogen or C 1-6-alkyl, it also can by phenyl or methyl-, methoxyl group-or the phenyl of halogen-replacement replace; R 11And R 12Can be identical or different, expression hydrogen, methyl, methoxyl group, phenyl, benzyl, nitro, cyano group, halogen, trifluoromethyl, amino, NR 10R 13, 1-pyrrolidyl, 1-pyrazolinyl, 1-tetrahydroglyoxaline, piperidino, 1-piperazinyl or formamyl, and R 11Also can represent to contain at the most 3 and be selected from methyl, methoxyl group, halogen, CF 3Substituent fused benzene rings with CN; R 13Expression hydrogen, halogen or C 1-4-alkyl, it also can be replaced by phenyl, phenoxy group or benzyloxy; Reaching E and G can be identical or different, expression N or CH; M represents 2,3,4,5 or 6, n represent 0 or 1 and p represent 2,3 or 4.
Alkyl in above-mentioned definition, alkenyl, alkynyl or alkylidene group can be straight or branched.Term " rudimentary " is meant to have 1-4, and particularly 1-3 is individual, more especially 1-2 carbon atom.Halogen is meant fluorine, chlorine and bromine, and fluorine and chlorine are particularly preferred.Preferred unsaturated alkyl is meant allyl group and propargyl.Letter m preferably represents 2,3 or 4, and p preferably represents 2 or 3.
This new compound can be different steric isomer or the form of suitable/anti--isomer exist, top general formula is represented its pure form and its mixture.The present invention includes all steric isomers or suitable/anti--isomeric forms, no matter it is optically pure or exists with its form of mixtures.
The typical R of the structure shown in below having 2-A-group is representational:
Figure A9419401600161
Figure A9419401600171
And, if A is connected to R by nitrogen-atoms 2On the group, group A exists usually so, wherein, and R 2Lian Jian is from carbon atom, suc as formula (II '), shown in (III ') and (IV ').
Can prepare this new compound by several different methods, these methods constituted of the present invention in addition-aspect.These methods comprise known several different methods itself.
The example of the inventive method is following a) to make following formula: compound
Figure A9419401600192
React with following formula amine
R 2-A-H (XVII) wherein, R 1And R 2Definition as above;
This reaction is carried out in water-free polar solvent or its mixture, is meant methyl-sulphoxide, dimethyl formamide especially, preferably carries out under the condition that is heating up in the presence of alkali such as triethylamine, N-methyl piperidine, the pyridine.
B) in order to prepare wherein R 2Be formula (I) compound of formula II, formula III or formula IV, can pass through radicals R 2Another nitrogen-atoms connect.For example, R wherein 2The compound of expression II group can be by making general formula X VIII acid amides (wherein A ' expression is connected to R by nitrogen-atoms 2The A group, suc as formula II ', III ' and IV ') (R wherein 1Definition as above)
Figure A9419401600201
Synthetic with the quinazoline derivant reaction
Figure A9419401600202
What adopt is that the described step c) of step (a) makes following formula: compound Wherein R represents low alkyl group or benzyl and R 1, R 2React with guanidine as mentioned above with the definition of A.
In reaction (c), reaction not only is confined to wherein R ester as defined above, just those skilled in the art should very ten thousand adopt the ester that is easy to prepare, as methyl esters or ethyl ester, or refers to the ester that the alcohol that obtains does not have problems when not influencing reaction or generation from ester.
The preferred alcohol that also contains in ester that uses for example makes the methyl ester of formula XX react in methyl alcohol under its boiling point as solvent in the reaction.This-method is best suited in the preparation The compounds of this invention.
When formula (I) compound is when occurring with steric isomer or other isomeric form, should adopt corresponding starting raw material.Perhaps, may in preparation process, form through separating the mixture can obtain each component.
Unknown starting raw material also can obtain by ordinary method, and for example, the N-amidino groups-methane amide with corresponding ester replacement formula XVI or XVII obtains formula XIX starting raw material.
Active substance in the formula I compound useful as drug composition, or as the intermediate for preparing these active substances.Here, new compound suppresses Na +/ H +-and Na +/ Li +-exchange.The compounds of this invention can be used as hypotensive agent, mucolytic agent, diuretic(s) and cancer stablizer (cancerostatics); They also can be used for treatment and local asphyxia diseases associated (for example the local asphyxia of heart, brain, gi tract, lung and kidney, liver local asphyxia, or the local asphyxia of whole-body muscle system).Corresponding disease comprises, for example the embolism in coronary heart disease, chest angina, the pulmonary circulation, acute or chronic renal failure, renal insufficiency, cerebral thrombosis are (for example with t-PA, bonded such as streptokinase, urokinase, the thrombus that after thrombus is opened, occurs after the recirculation of blood by brain), the acute and chronic circulatory disorders of brain.In order to compensate ischemic heart (for example after stenocardia or myocardial infarction outbreak), myocardial cell's irreversible damage appears in affected zone.In addition, The compounds of this invention is used in particular for Cardioprotective in these cases.The superiority of new compound is the side effect that it is minimum, and it is noticeable especially that α 1-and/or α 2-effect essence do not exist.
About ischemic Application Areas also comprises for the protection of transplanting associated injury (for example in migration process and transplant afterwards protection to transplant organ).
Active substance can be used by regular dosage form, the tablet of regular dosage form such as conventional tablet or coating, capsule, granula, injection liquid or if possible, the preparation of nasal administration.The content of active substance of per unit dosage is 1-200mg normally, preferred 20-100mg.The pharmaceutical composition that contains with the physiologically acceptable carrier of The compounds of this invention bonded, thinner or vehicle has constituted another aspect of the present invention content.
These pharmaceutical dosage forms can prepare according to known method, and by following non-limiting example explanation.
Medicine embodiment
1, tablet (composition)
Embodiment compound 40.0mg
W-Gum 144.0mg
Sec calcium phosphate 115.0mg
Magnesium Stearate 1.0mg
300mg
2, gelatine capsule
Capsule is made up of the beautiful starch of the The compounds of this invention of 50.0mg and 150.0mg.
Following synthetic embodiment has illustrated an aspect of of the present present invention content.
Following table has been listed from formula (Ia) derived compounds:
Figure A9419401600231
* embodiment 1 (method is N-[2-(6,7-dimethoxy-4 '-quinazolyl)-N '-[5-[2-(N-amidino groups-formamyl)-3-amino-6-chlorine] pyrazinyl a)]-N, N piperazine-hydrochloride
Figure A9419401600232
Make the 3-amino-5 of 285.5mg (1mmol); 6-dichloropyrazine acyl group-2-guanidine-hydrochloride and 326.8mg 3-piperazinyl-(6; 7-dimethoxy-quinazoline-4-yl) hydrochloride in the 10ml dimethyl formamide, in the presence of the 100mg triethylamine, heated 2 hours to 90-100 ℃ together.
Behind the cool to room temperature, the product of filtering for crystallizing obtains the 480mg reaction product.Product is suspended in the 5ml methyl alcohol, and adds methanolic hydrochloric acid to generate corresponding hydrochloride.Add 2.5ml water temperature heat (warning up) and obtain clear soln, therefrom obtain the title compound of 350mg after the cooling, fusing point 260-263 ℃.
Embodiment 2N-[2-(4-amino-6,7-dimethoxy) quinazolyl]-N '-[5-[2-(N-amidino groups-formamyl)-3-amino-6-chlorine] pyrazinyl]-N, N '-dimethyl-1-hydrochloride * a) make 7.2g (30mmol) 1-amino-3-chloro-6, the 7-dimethoxyquinazoline, 13.2g (150mmol) N, N '-dimethyl-ethylenediamine refluxed 1 hour in the 60ml Pentyl alcohol, and steaming desolventizes and residue is dissolved in the 100ml acetonitrile solution then, filters.Crystallize out by crude product in the middle of the cooling reaction 6.05g, again it is dissolved in the water that 60ml refluxes, add recrystallized product behind the 80ml, separate the pure N-[(4-amino-6 that obtains 3.9g, the 7-dimethoxy)-the 2-quinazolyl]-N, N '-dimethyl-1.B) with the N-[(4-amino-6 of 5.83 (20mmol), the 7-dimethoxy)-the 2-quinazolyl]-N, N '-dimethyl-1, the 2-diaminoethanes, 4.44g 3-amino-5 (20mmol), the triethylamine of 6-dichloropyrazine-2-carboxylate methyl ester and 2.75ml (20mmol) is dissolved in the 30ml methyl-sulphoxide, and under agitation heats 2 hours to 80 ℃.After the cooling, add 60ml water, by the reaction product of suction strainer precipitation separation.After the drying, need not be further purified and make material (product 9.1g) reaction that obtains, prepare guanidine derivative.C) under the room temperature, 9.07g (95mmol) guanidine-hydrochloride was stirred 30 minutes in the sodium methoxide solution of 95ml (95mmol) 1N methanolizing, remove the sodium-chlor precipitation by suction strainer.Make filtrate and 9.1g (19.1mmol) 3-amino-6-chloro-5-[2-[(4-amino-6, the 7-dimethoxy)-the 2-quinazolyl]-1-(N, N '-dimethyl-1, the 2-diamino ethyl)]-pyrazine-2-carboxylate methyl ester mixed 100-110 ℃ of heating 3 hours that are incorporated in the 50ml dimethyl formamide, the residue that obtains after steaming desolventizes purifying on silicagel column, eluent: ethyl acetate 70/ Virahol 30/NH 4OH 10. is dissolved in ethanol also with the hcl acidifying in the ether, by adding the ether crystalline hydrochloride with the material behind the purifying.Productive rate 5.4g, fusing point 227-230 ℃.
Compound listed in the following table can prepare according to the data of the foregoing description and/or specification sheets.
Table 1
R wherein 2-A is the formula Ia compound N o. m R of formula II ' group 4R 4Mp.[℃] 12 H H＞2,202 2 CH 3H3 2 H CH 342 CH 3CH 3227-305 2 CH 3C 2H 562 C 2H 5CH 372 C 2H 5C 2H 582 i-C 3H 7CH 392 CH 3I-C 3H 710 2 i-C 3H 7I-C 3H 711 3 H CH 312 3 CH 3H13 3 CH 3CH 314 3 C 2H 5CH 315 3 CH 3C 2H 516 3 C 2H 5C 2H 517 3 i-C 3H 7CH 318 3 CH 3I-C 3H 719 3 i-C 3H 7I-C 3H 720 6 CH 3CH 3190-221 3 n-C 4H 9N-C 4H 9
Table 2
R wherein 2-A is the formula Ia compound N o. R of formula III ' group 4' R 4Configuration Mp.[℃] 1 H H cis, 2 CH 3H cis 3 H CH 3Cis 4 CH 3CH 3Cis 5 n-C 3H 7N-C 3H 7Cis 6 H H trans 7 CH 3H trans 8 H CH 3Trans 9 CH 3CH 3Trans10 n-C 3H 7N-C 3H 7Trans11 i-C 4H 9H cis/trans12 H t-C 4H 9Cis/trans
Annotate: cis is a cis, and trans is trans
Table 3
R wherein 2-A is the formula Ia compound N o. m n R of formula VI ' group 4Mp.[℃] 120 H, 220 CH 3320 C 2H 5420 i-C 3H 7520 C 6H 5621 H, 721 CH 3821 C 2H 5921 i-C 3H 710 21 C 6H 511 30 H12,30 CH 313 30 C 2H 514 30 i-C 3H 715 30 C 6H 516 31 H17,31 CH 318 31 C 2H 519 31 i-C 3H 720 31 C 6H 5
Table 4
R wherein 2-A is formula V ' group, R 3Be that hydrogen and p are 2 formula Ia compound N o. m R 4' R 4Mp.[℃] 12 H H, 22 CH 3CH 332 C 2H 5C 2H 542 i-C 3H 7I-C 3H 752 C 6H 5CH 363 H H, 73 CH 3CH 383 C 2H 5C 2H 593 i-C 3H 7I-C 3H 710 3 C 6H 5CH 311 2 n-C 4H 9CH 312 2 C 6H 5C 6H 5
Table 5
R wherein 2-A is the formula Ia compound N o. m R of formula VI ' group 4R 3Mp.[℃] 12 H H, 22 CH 3CH 332 C 2H 5C 2H 542 i-C 3H 7I-C 3H 752 C 6H 5CH 363 H H, 73 CH 3CH 383 C 2H 5C 2H 593 i-C 3H 7I-C 3H 710 3 C 6H 5CH 311 2 n-C 4H 9CH 312 2 C 6H 5C 6H 5
Table 6
R wherein 2The formula Ia compound of-A expression VII ' group
Figure A9419401600311
No. R 8R 9Mp.[℃] 1 H H2 CH 3Cl3 Cl Cl4 CH 3CH 3
Table 7
R wherein 2The formula Ia compound of-A expression VIII ' group No. R 9Mp.[℃] 1 H2 Cl3 CH 3
Table 8
R wherein 2The formula Ia compound (R of-A expression IX ' group 11/ R 12
The location is for phenyl) No. R 10R 11R 12Mp.[℃] 1 H H H, 2 H 3-Cl H, 3 H 2-F 3-F, 4 H 4-NO 2H 5 H 4-CN H 6 H 3-OCH 34-OCH 37 H CH 3H 8 H 4-F 3-C 2H 59 H 4-CH 2-C 6H 5H10 H 4-OCH 32-CH 2-C 6H 511 CH 3H H12 CH 33-Cl H13 CH 32-F 3-F14 CH 34-NO 2H15 CH 34-CN H16 CH 33-OCH 34-OCH 317 CH 3CH 3H18 CH 34-F 3-C 2H 519 CH 34-CH 2C 6H 5H20 CH 34-OCH 32-CH 2-C 6H 521 C 2H 5H H22 C 2H 53-Cl H23 C 2H 52-F 3-F24 C 2H 54-NO 2HNo. R 10R 11R 12Mp.[℃] 25 C 2H 54-CN H26 C 2H 53-OCH 34-OCH 327 C 2H 5CH 3H28 C 2H 54-F 3-C 2H 529 C 2H 54-CH 2C 6H 5H30 C 2H 54-OCH 32-CH 2-C 6H 531 i-C 3H 7H H32 n-C 6H 134-F H33 4-F-C 6H 44-F H34 CH 2-C 6H 54-F H35 C 2H 54-F H36 n-C 4H 92-CH 36-CH 3
Table 9
R wherein 2The formula Ia compound of-A expression X ' group (R 3And R 9Expression H) No. R 8R 13Mp.[℃] 1 H H2 C 2H 5H3 H CH 34 i-C 3H 7H5 H CH 36 H Br7 Br H8 CH 3H
Table 9a
R wherein 2The formula Ia compound of-A expression X ' group (R 3And R 9Expression H) No. R 8R 13Mp.[℃] 1 H H2 C 2H 5H3 H CH 34 i-C 3H 7H5 i-C 3H 7CH 36 H Br7 Br H8 CH 3H
Table 10
R wherein 2The formula Ia compound of-A expression XI ' group
Figure A9419401600371
No. R 11R 12Mp.[℃] 1 NH 2H 275-82 CONH 2H3 Cl H4 Cl Cl5 H H 288-906 H CH 37 CH 3H8 CN H 239-419 CH 3CH 3
Table 11
R wherein 2The formula Ia compound of-A expression XII ' or XIII ' group
Figure A9419401600381
R wherein 14And R 15Represent radicals R respectively 3And R 4, but also can represent jointly-CH 2-CH 2-CH 2-CH 2-No. R 14R 15Form Mp.[℃] 1 H CH 32 CH 3H 3 CH 3CH 3Along 4 CH 3CH 3Anti-5 C 2H 5CH 3Suitable/anti-6 C 2H 5C 2H 5Along 7 C 2H 5C 2H 5Anti-8 H H x2HCl 295-310 (D), 9 H i-C 3H 710-CH 2-CH 2-CH 2-CH 2-along 11-CH 2-CH 2-CH 2-CH 2-anti-
Table 12
R wherein 2The formula Ia compound of-A expression XIV ' group, R 5And R 6The location be No. R for the quinazolinone ring system 7R 5R 6Mp.[℃] 1 H H H 260-3,2 H 6-OCH 37-OCH 33 H 8-OCH 3H 4 H 6-OH 7-OH 5 H 7-OH H 6 H 8-OH H 7 H 6-Cl H 8 H 6-CH 37-CH 39 CH 3H H10 CH 36-OCH 37-OCH 311 CH 38-OCH 3H12 CH 36-OH 7-OH13 CH 37-OH H14 CH 38-OH H15 CH 36-Cl H16 CH 36-CH 37-CH 3
Table 13
R wherein 2The formula Ia compound N o. m R of-A expression XV ' group 3Mp.[C] 12 H 260-262,22 CH 332 H, 42 CH 352 n-C 4H 962 H, 73 H, 83 CH 393 H10,3 CH 311 3 n-C 4H 912 3 H
Table 14
R 2Represent that multiple group and A represent the formula Ia compound of following formula group
Figure A9419401600411
Figure A9419401600412
Table 15
R 2The formula Ia compound that is defined as follows for formula III ' group and A

Claims (8)

1, formula (I) compound and acid salt thereof, with and single steric isomer or suitable/anti--isomer and/or these mixture of isomers:
Figure A9419401600021
Wherein A represents to be connected in by nitrogen-atoms the following radicals of Zinamide system :-C mH 2m-NR 4-,-C mH 2m-NR 4-C pH 2p-NR 4'-,
Figure A9419401600022
-NR 4-C mH 2m-NR 4'-
Figure A9419401600031
R 1Expression hydrogen, fluorine, chlorine, C 1-4-alkyl, C 3-7Cycloalkyl, C 1-4-alkoxyl group, trifluoromethyl, phenyl, benzyl, phenyl-low alkyl group, phenyl-low-grade alkenyl, phenyl-low-grade alkynyl or phenoxy group, wherein phenyl can contain at the most 3 and is selected from C 1-4-alkyl, C 1-4-alkoxyl group, CF 3, F, Cl or CN substituting group; R 2Expression following formula group
Figure A9419401600032
Figure A9419401600051
Figure A9419401600061
R wherein 3, R 4And R 4' can be identical or different, expression hydrogen or C 1-4-alkyl, or R 4Or R 4' also can represent phenyl, benzyl or C 3-7-cycloalkyl; R 5And R 6Can be identical or different, expression hydrogen, methyl, methoxyl group, hydroxyl or halogen; R 7Show hydrogen, C 1-4-alkyl, benzyl or benzyloxy; R 8And R 9Identical or different, expression hydrogen, C 1-4-alkyl, phenyl or halogen; R 10Expression hydrogen or C 1-6-alkyl, it also can by phenyl or methyl-, methoxyl group-or the phenyl of halogen-replacement replace; R 11And R 12Can be identical or different, expression hydrogen, methyl, methoxyl group, phenyl, benzyl, nitro, cyano group, halogen, trifluoromethyl, amino, NR 10R 13, 1-pyrrolidyl, 1-pyrazolinyl, 1-tetrahydroglyoxaline, piperidino, 1-piperazinyl or formamyl, and R 11Also can represent to contain at the most 3 and be selected from methyl, methoxyl group, halogen, CF 3Substituent fused benzene rings with CN; R 13Expression hydrogen, halogen or C 1-4-alkyl, it also can be replaced by phenyl, phenoxy group or benzyloxy; Reaching E and G can be identical or different, expression N or CH; M represents 2,3,4,5 or 6, n represent 0 or 1 and p represent 2,3 or 4.
2, the described formula of claim 1 (I) compound, wherein R 2-A expression II ' is to formula XV ' group and R 3, R 4And R 4' can be identical or different, expression hydrogen or C 1-C 3Alkyl.
3, the described formula of claim 1 (I) compound, wherein R 2Expression XI group and G or E represent N.
4, formula (Ia) compound
Figure A9419401600071
R wherein 2Definition such as claim 1 with A.
5, the pharmaceutical composition that contains the arbitrary described compound of claim 1-4 and physiologically acceptable thinner, vehicle and/or carrier.
6, the application of the arbitrary described compound of claim 1-4 in pharmaceutical compositions.
7, the arbitrary described compound of claim 1-4 is as hypotensive agent, mucolytic agent, diuretic(s) and cancerostatic agent; in treatment and local asphyxia diseases associated; cerebral thrombosis, acute and chronic brain circulatory diseases is at Cardioprotective with in the application that prevents to transplant aspect the infringement.
8, the method for formula (I) compound of preparation claim 1 definition, this method comprises: (a) make formula (XVI) compound
Figure A9419401600081
R wherein 1Definition such as the reaction of claim 1 and formula (XVII) amine
R 2-A-H (XVII) is A and R wherein 2Definition such as claim 1; Or (b) in order to prepare the wherein R of claim 1 definition 2Be formula II, formula (I) compound of formula III or formula IV makes general formula (XVIII) amine
Figure A9419401600082
Wherein A ' expression is connected to R by nitrogen-atoms 2A group on the carbon atom, and R 1Definition according to claim 1, react with formula (XIX) compound Perhaps (c) makes formula (XX) compound
Figure A9419401600092
Wherein R represents low alkyl group or benzyl, and is necessary and/or when needing subsequently with guanidine reaction, separated product obtain its different three-dimensional form and/or arbitrarily the alkali of formula (I) change into its acid salt, maybe the salt that obtains is converted into free alkali.
CN94194016A 1993-11-04 1994-10-31 Pyrazine carboxamide derivs., their production and their use in medicaments Pending CN1134151A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4337609.6 1993-11-04
DE4337609A DE4337609A1 (en) 1993-11-04 1993-11-04 Novel pyrazinecarboxamide derivatives, their preparation and their use in medicines

Publications (1)

Publication Number Publication Date
CN1134151A true CN1134151A (en) 1996-10-23

Family

ID=6501757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194016A Pending CN1134151A (en) 1993-11-04 1994-10-31 Pyrazine carboxamide derivs., their production and their use in medicaments

Country Status (17)

Country Link
EP (1) EP0726899B1 (en)
JP (1) JPH09505035A (en)
KR (1) KR960705815A (en)
CN (1) CN1134151A (en)
AT (1) ATE188965T1 (en)
AU (1) AU690588B2 (en)
CA (1) CA2175837A1 (en)
CO (1) CO4290432A1 (en)
DE (2) DE4337609A1 (en)
DK (1) DK0726899T3 (en)
ES (1) ES2140565T3 (en)
GR (1) GR3033034T3 (en)
NZ (1) NZ274848A (en)
PL (1) PL314187A1 (en)
PT (1) PT726899E (en)
WO (1) WO1995012592A1 (en)
ZA (1) ZA948669B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103467392A (en) * 2013-10-09 2013-12-25 重庆工商大学 Polyhalogenated pyrazinecarboxamide derivative and salts, preparation method and application thereof

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548812A1 (en) * 1995-12-27 1997-07-03 Hoechst Ag Use of inhibitors of the cellular Na · + · / H · + · exchanger (NHE) for the manufacture of a medicament for respiratory stimulation
DE19738604A1 (en) * 1997-09-04 1999-03-11 Hoechst Marion Roussel De Gmbh Use of Na<+>/H<+> exchange inhibitors
US6706732B1 (en) 1999-06-03 2004-03-16 Takeda Chemical Industries, Ltd. Nasal preparation of guanidinoimino quinoline derivatives
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
MXPA04010288A (en) 2002-04-19 2005-05-17 Cellular Genomics Inc IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF.
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
RU2006102869A (en) 2003-07-02 2007-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Arylamino-substituted quinazolinone compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
AU2004276341B2 (en) 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
RS55055B1 (en) 2008-12-08 2016-12-30 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
NZ593460A (en) 2008-12-08 2013-11-29 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
NZ602362A (en) 2010-03-11 2014-11-28 Gilead Connecticut Inc Imidazopyridines syk inhibitors
PL2616460T3 (en) 2010-09-13 2016-03-31 Otsuka Pharma Co Ltd Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
AP2016009007A0 (en) 2013-07-30 2016-01-31 Gilead Connecticut Inc Formulation of syk inhibitors
KR101810798B1 (en) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Polymorph of syk inhibitors
EA201690608A1 (en) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. METHODS OF TREATMENT OF CANCER DISEASES
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (en) 2013-12-23 2015-07-31 Gilead Sciences Inc ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?.
KR20170029580A (en) 2014-07-14 2017-03-15 길리애드 사이언시즈, 인코포레이티드 Combinations for treating cancers
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
KR20210131372A (en) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Solid Form of Condensed Pyrazine as Syk Inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299931A (en) * 1962-10-30
TW213903B (en) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103467392A (en) * 2013-10-09 2013-12-25 重庆工商大学 Polyhalogenated pyrazinecarboxamide derivative and salts, preparation method and application thereof
CN103467392B (en) * 2013-10-09 2016-08-17 重庆工商大学 A kind of polyhalo pyrazinecarboxamide derivatives and its esters, preparation method and purposes

Also Published As

Publication number Publication date
AU690588B2 (en) 1998-04-30
PL314187A1 (en) 1996-09-02
DK0726899T3 (en) 2000-06-26
CA2175837A1 (en) 1995-05-11
DE4337609A1 (en) 1995-05-11
JPH09505035A (en) 1997-05-20
ATE188965T1 (en) 2000-02-15
GR3033034T3 (en) 2000-08-31
WO1995012592A1 (en) 1995-05-11
PT726899E (en) 2000-04-28
EP0726899A1 (en) 1996-08-21
ZA948669B (en) 1995-07-04
DE59409094D1 (en) 2000-02-24
KR960705815A (en) 1996-11-08
AU7993694A (en) 1995-05-23
ES2140565T3 (en) 2000-03-01
NZ274848A (en) 1998-03-25
EP0726899B1 (en) 2000-01-19
CO4290432A1 (en) 1996-04-17

Similar Documents

Publication Publication Date Title
CN1134151A (en) Pyrazine carboxamide derivs., their production and their use in medicaments
CN1056609C (en) Benzoyl guanidines, their production and their use in medicaments
HU209470B (en) Processe for preparing indane and quinoline derivatives
EP0898568A1 (en) 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
CN108948020A (en) Refining method of tofacitinib citrate
CN1179422A (en) New flavone compounds, process for preparing them and pharmaceutical compositions containing them
EP0527081B1 (en) Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazine-4-ones, their preparation and their therapeutical use
CN1211974A (en) Quinoline-2-(1H)-ones
JPS61109766A (en) Adamantaneamine derivative, manufacture and medicine
US4314943A (en) Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
CA1228359A (en) Process for preparing new quinoline derivatives
CN1009826B (en) The method for preparing quinoline compound
CN1063177C (en) Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
US6242448B1 (en) Trisubstituted-oxazole derivatives as serotonin ligands
EP1861367B1 (en) An improved process for the purification of perindopril
JP2871811B2 (en) 7-membered condensed ring compound
CN102803253A (en) 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
JP2002538154A (en) N-substituted imide derivatives having serotonin agonist activity
CN1774420B (en) Process for the preparation of N-substituted 2-cyanopyrrolidines
CN1030077A (en) Famotidine pyridine polymorphic form and preparation method thereof
CN101085779A (en) Substituted indole-3-oxalylepipodophyllotoxin derivative, salt and application thereof
JPH11507952A (en) N-aminoalkyl-2-anthraquinone carboxamides; new ligands specific for dopamine receptor subtype
CA2166470C (en) Pharmacologically active enantiomers
CN114874232B (en) Preparation method and application of thienopyrimidinone compound containing ethyl naphthalene structure
JPH11507064A (en) Novel N-aminoalkyl-2-anthracenecarboxamides; Novel dopamine receptor subtype-specific ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication